Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy
Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy
复制标题
DOI：
10.1111/j.1600-0609.2008.01099.x
复制
发表时间：
2008-09-01
影响因子：
3.1
通讯作者：
Kim, Byung Soo
中科院分区：
文献类型：
--
作者：
Kim, Seok Jin;Lee, Seung Jin;Kim, Byung Soo
目的：肿瘤坏死因子家族的B细胞活化因子（BAFF）和增殖诱导配体（APRIL）调节B细胞的存活和增殖。因此，在B细胞淋巴恶性肿瘤中，BAFF和APRIL血清水平升高与预后不良相关。然而，BAFF和APRIL的预后相关性是未知的利妥昔单抗，靶向B细胞depletion.Methods单克隆抗体治疗的患者：我们测定了BAFF和APRIL的血清水平在66例新诊断为弥漫性大B细胞淋巴瘤（DLBCL）。结果：DLBCL患者血清BAFF水平（1970.21 ± 1979.45 pg/mL）明显高于对照组（861.03 ± 194.92 pg/mL）（P < 0.001）;当患者根据中位数（1 258.00 pg/mL）分为高BAFF组和低BAFF组时，高BAFF组对利妥昔单抗-CHOP的完全应答人数较少，并且治疗后或治疗期间复发或进展较多。多因素分析中，血清BAFF是影响总生存期和无进展生存期的独立预后因素（P < 0.05）。虽然APRIL的血清水平也高于对照组（10.60 +/- 19.08 ng/mL vs.1.10 +/- 0.30 ng/mL，P = 0.023），它未能显示预后significant.Conclusions：血清BAFF可能是一个有用的指标预测DLBCL患者与利妥昔单抗治疗的预后。
Objectives: B-cell activating factor of the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) regulate survival and proliferation of B cells. Thus the association of elevated serum levels of BAFF and APRIL with worse prognosis has been suggested in B-cell lymphoid malignancies. However, the prognostic relevance of BAFF and APRIL is unknown in patients treated with rituximab, a monoclonal antibody targeting B-cell depletion.Methods: We measured serum levels of BAFF and APRIL by enzyme-linked immunosorbent assay in 66 patients newly diagnosed as diffuse large B-cell lymphoma (DLBCL). All patients were treated with rituximab-CHOP chemotherapy.Results: The mean (+/- standard deviation) serum level of BAFF (1 970.21 +/- 1 979.45 pg/mL) was higher in DLBCL than in controls (861.03 +/- 194.92 pg/mL, Mann-Whitney U-test, P < 0.001). When the patients were dichotomized into high and low BAFF group based on the median value (1 258.00 pg/mL), high BAFF group had less numbers of complete responders to rituximab-CHOP, and more relapses or progression after or during treatment. In multivariate analysis, serum BAFF was an independent prognostic factor for overall survival and progression-free survival (P < 0.05). Although serum levels of APRIL was also higher than controls (10.60 +/- 19.08 ng/mL vs. 1.10 +/- 0.30 ng/mL, P = 0.023), it failed to show prognostic significance.Conclusions: Serum BAFF may be a useful indicator predicting prognosis in DLBCL patients treated with rituximab-containing chemotherapy.